Market Closed -
Nasdaq
16:00:00 2024-05-10 EDT
|
5-day change
|
1st Jan Change
|
4.34
USD
|
-3.77%
|
|
-0.91%
|
+141.11%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
353.3
|
46.7
|
79.75
|
255.5
|
-
|
-
|
Enterprise Value (EV)
1 |
78.6
|
-134.1
|
79.75
|
255.5
|
255.5
|
255.5
|
P/E ratio
|
-4.74
x
|
-0.37
x
|
-0.97
x
|
-5.69
x
|
-3.4
x
|
-3.21
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
71
x
|
639
x
|
37.9
x
|
EV / Revenue
|
-
|
-
|
-
|
71
x
|
639
x
|
37.9
x
|
EV / EBITDA
|
-5,115,596
x
|
-380,378
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-9,851,510
x
|
-487,808
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
1.38
x
|
0.29
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
32,209
|
34,851
|
44,304
|
58,876
|
-
|
-
|
Reference price
2 |
10.97
|
1.340
|
1.800
|
4.340
|
4.340
|
4.340
|
Announcement Date
|
22-03-29
|
23-03-22
|
24-03-21
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
3.6
|
0.4
|
6.75
|
EBITDA
|
-
|
-69.07
|
-122.8
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-69.72
|
-123.5
|
-82.2
|
-70.47
|
-84.17
|
-114.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,957.59%
|
-21,041.85%
|
-1,694.58%
|
Earnings before Tax (EBT)
1 |
-
|
-75.98
|
-120.7
|
-73.79
|
-51.11
|
-79.19
|
-114.5
|
Net income
1 |
-12.83
|
-75.98
|
-120.7
|
-73.79
|
-51.11
|
-79.19
|
-114.5
|
Net margin
|
-
|
-
|
-
|
-
|
-1,419.8%
|
-19,797.69%
|
-1,695.75%
|
EPS
2 |
-1.960
|
-2.313
|
-3.650
|
-1.850
|
-0.7633
|
-1.277
|
-1.350
|
Free Cash Flow
|
-
|
-35.87
|
-95.73
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-06-21
|
22-03-29
|
23-03-22
|
24-03-21
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3.3
|
0.1
|
0.1
|
0.1
|
0.5
|
EBITDA
|
-
|
-16.27
|
-31.23
|
-25.57
|
-28.19
|
-37.78
|
-
|
-17.6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.62
|
-16.43
|
-31.39
|
-25.73
|
-28.39
|
-37.97
|
-20.95
|
-18.12
|
-25.35
|
-17.77
|
-14.43
|
-18.37
|
-18.87
|
-19.01
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-437.41%
|
-18,366.2%
|
-18,865.8%
|
-19,007.2%
|
-
|
Earnings before Tax (EBT)
1 |
-14.18
|
-16.83
|
-31.38
|
-25.56
|
-27.67
|
-36.1
|
-19.24
|
-15.9
|
-23.05
|
-15.6
|
-12.14
|
-14.44
|
-12.4
|
-12.39
|
-
|
Net income
1 |
-14.18
|
-16.83
|
-31.38
|
-25.56
|
-27.67
|
-36.1
|
-19.24
|
-15.9
|
-23.05
|
-15.6
|
-12.14
|
-14.44
|
-12.4
|
-12.39
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-367.78%
|
-14,442.5%
|
-12,396.25%
|
-12,387%
|
-
|
EPS
2 |
-0.4470
|
-0.5700
|
-0.9700
|
-0.7900
|
-0.8500
|
-1.040
|
-0.5400
|
-0.4100
|
-0.5600
|
-0.3300
|
-0.1833
|
-0.2267
|
-0.1833
|
-0.1733
|
-0.3500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-15
|
22-03-29
|
22-05-13
|
22-08-15
|
22-11-01
|
23-03-22
|
23-05-11
|
23-08-11
|
23-11-07
|
24-03-21
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
275
|
181
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-35.9
|
-95.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-61.9%
|
-57.2%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
7.970
|
4.600
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-4.160
|
-2.700
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.54
|
-
|
6.73
|
4.26
|
3.48
|
7.09
|
Capex / Sales
|
-
|
-
|
-
|
-
|
118.31%
|
869%
|
104.96%
|
Announcement Date
|
21-06-21
|
22-03-29
|
23-03-22
|
24-03-21
|
-
|
-
|
-
|
Last Close Price
4.34
USD Average target price
8
USD Spread / Average Target +84.33% Consensus |
1st Jan change
|
Capi.
|
---|
| +141.11% | 256M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|